Home › Funds › Bain Capital Life Sciences Investors, LLC › PHVS

Bain Capital Life Sciences Investors, LLC position in PHVS

PHARVARIS N V · Health Care

Bain Capital Life Sciences Investors, LLC reported holding 2,475,509 shares of PHVS (PHARVARIS N V) in its Q3 2026 13F filing — a position valued at US$76.9M, representing 5.30% of its reported portfolio and ranking #8 among its reported holdings. Bain Capital Life Sciences Investors, LLC has disclosed PHVS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)2.48M sh
Reported value held$76.92M
Portfolio Weight5.30%
First reportedQ3 2023
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Bain Capital Life Sciences Investors, LLC's PHVS position evolved

Bain Capital Life Sciences Investors, LLC first disclosed a stake in PHVS in Q3 2023 at 4,784,674 shares (US$99.9M). The position peaked in Q4 2023 at 3,904,319 shares, worth US$109.5M. Across 13 filings, Bain Capital Life Sciences Investors, LLC increased the stake 0 time(s), trimmed it 6 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 2,475,509 shares valued at US$76.9M — a reduction of -200,000 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 4.78M $99.86M New
Q4 2023 3.90M $109.52M Reduce
Q1 2024 3.30M $76.34M Reduce
Q2 2024 3.30M $62.10M Hold
Q3 2024 3.30M $61.18M Hold
Q4 2024 3.30M $63.33M Hold
Q1 2025 3.30M $51.86M Hold
Q2 2025 3.30M $58.14M Hold
Q3 2025 3.18M $79.37M Reduce
Q4 2025 2.80M $77.76M Reduce
Q1 2026 2.68M $75.58M Reduce
Q2 2026 2.68M $92.52M Hold
Q3 2026 2.48M $76.92M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PHVS and 13F data

PHVS (PHARVARIS N V) is a Health Care company. 51 other funds we track also report a position in PHVS — the largest reported positions include Foresite Capital Management IV, LLC (US$165.2M), venBio Partners LLC (US$160.6M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$116.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PHVS

All PHVS fund holders →

FAQ

How long has Bain Capital Life Sciences Investors, LLC held PHVS?

Bain Capital Life Sciences Investors, LLC has disclosed PHVS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Bain Capital Life Sciences Investors, LLC's current position in PHVS?

As of Q3 2026, Bain Capital Life Sciences Investors, LLC holds 2.48M shares of PHVS (PHARVARIS N V), valued at $76.92M, representing 5.30% of its reported portfolio and ranking #8.

Has Bain Capital Life Sciences Investors, LLC been buying or selling PHVS?

In the latest 13F filing (Q3 2026), Bain Capital Life Sciences Investors, LLC reduced its position in PHVS. The position peaked in Q4 2023 at 3.90M shares.

Which other funds hold PHVS?

Other major institutional holders of PHVS include Foresite Capital Management IV, LLC, venBio Partners LLC, DEERFIELD MANAGEMENT COMPANY, L.P., among 51 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.